MTT-Based Assessment of the Anticancer Potential of a Known 1,2-Disubstituted Benzimidazole Compound on DLD-1 Cell Line
Bozok Journal of Science · 2025
DOI: 10.70500/bjs.1799229 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bozok Journal of Science, 2025. Verfasst von Yasemin Sunucu Karafakıoğlu und 3 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Süleyman Demirel University.
Abstract (Originalsprache)
In this study, the cytotoxic effect of 1-(4-methylbenzyl)-2-p-tolyl-1H-benzo[d]imidazole (SL-13) was investigated on human colorectal cancer DLD-1 cells using the MTT assay. Treatment with SL-13 at various concentrations (100, 50, and 25 µM) for 72 hours resulted in a potent cytotoxic response with an IC₅₀ value of 6.093 µM, indicating strong antiproliferative activity. This potency surpasses that reported for many other benzimidazole derivatives tested against DLD-1 cells. These findings show that SL-13 is a promising candidate for further development in colorectal cancer therapy, warranting additional mechanistic and in vivo studies to elucidate its therapeutic potential.
Förderung
- Süleyman Demirel University
Zitieren
APA
Karafakıoğlu, Y. S., Akgün, E. E., Nane, İ. D., & Akkoç, S. (2025). MTT-Based Assessment of the Anticancer Potential of a Known 1,2-Disubstituted Benzimidazole Compound on DLD-1 Cell Line. Bozok Journal of Science. https://doi.org/10.70500/bjs.1799229
Vancouver
Karafakıoğlu YS, Akgün EE, Nane İD, Akkoç S. MTT-Based Assessment of the Anticancer Potential of a Known 1,2-Disubstituted Benzimidazole Compound on DLD-1 Cell Line. Bozok Journal of Science. 2025. doi:10.70500/bjs.1799229
BibTeX
@article{Karafakolu2025,
author = {Karafakıoğlu, Yasemin Sunucu and Akgün, Elif Ece and Nane, İkbal Demet and Akkoç, Senem},
title = {MTT-Based Assessment of the Anticancer Potential of a Known 1,2-Disubstituted Benzimidazole Compound on DLD-1 Cell Line},
journal = {Bozok Journal of Science},
year = {2025},
doi = {10.70500/bjs.1799229}
}
EUVIMED